Bull, base and bear scenarios, opening on what this business has actually done — its realised growth rates and its own P/E range, not round numbers we chose.
Projections are part of Pro
Set the growth, margin and multiple yourself and watch the price land where your assumptions put it — for Novo Nordisk A/S and every other company we cover.
Try it first on NVDA, AAPL, META, NKE or CAKE, where it is open to everyone.
$41.64+2.4%Nov 13 close
Figures through September 30, 2026, from the 6-K filed November 4, 2026
Novo Nordisk sells prescription medicines for diabetes and obesity to patients and the health systems, insurers and pharmacies that pay for them.